Exabis Library:

Welcome to the e-CCO Library!

Search by:

All Congress AbstractsCongress SlidesTools & SkillsVideos & Podcasts

Year: Category:

OP010: Shallow whole-genome sequencing predicts the future cancer risk of low-grade dysplastic lesions arising in ulcerative colitis

Year: 2018

Source: ECCO '18 Vienna

Authors:

I. Al Bakir¹,²*, K. Curtius¹, A.-M. Baker¹, T.S.O. Clarke¹, M. Moorghen³, M. Jansen⁴, M. Rodriguez-Justo⁴, S. Leedham⁵, T. Graham¹*, A. Hart²*

Created: Thursday, 21 February 2019, 9:14 AM

OP011: Comparison of adalimumab monotherapy and a combination with azathioprine for patients with Crohn’s disease: a prospective, multicentre, open-labelled clinical trial (DIAMOND study)

Year: 2016

Source: ECCO '16 Amsterdam

Authors:

T. Matsumoto*¹, S. Motoya², K. Watanabe³, T. Hisamatsu⁴, H. Nakase⁵, N. Yoshimura⁶, T. Ishida⁷, S. Kato⁸, T. Nakagawa⁹, M. Esaki¹⁰, M. Nagahori¹¹, T. Matsui¹², Y. Naito¹³, T. Kanai¹⁴, Y. Suzuki¹⁵, M. Nojima¹⁶, M. Watanabe¹¹, T. Hibi¹⁷

Created: Friday, 22 February 2019, 9:49 AM

OP011: Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study

Year: 2017

Source: ECCO '17 Barcelona

Authors:

Peyrin-Biroulet L.^*1, Feagan B.G.², Mansfield J.³, Rubin D.T.⁴, Arulmani U.⁵, Maciuca R.⁵, Tyrrell H.⁶, Thommes J.⁵, Tole S.⁶

Created: Wednesday, 20 February 2019, 10:36 AM

OP011: Integration of whole exome sequencing and RNA sequencing of intestinal biopsies in Inflammatory Bowel Disease identifies inflammation dependent effects

Year: 2018

Source: ECCO'18 Vienna

Authors: Barbieri Ruggero

Created: Friday, 23 March 2018, 12:23 PM

Files: 1

OP011: Integration of whole-exome sequencing and RNA sequencing of intestinal biopsies in inflammatory bowel disease identifies inflammation-dependent effects

Year: 2018

Source: ECCO '18 Vienna

Authors:

R. Barbieri¹*, W. Uniken Venema¹, A. Vich Vila¹, Y. Li¹, L. Franke¹, F. van Dijk¹, N. De Klein¹, M. Swertz¹, S. Sanna¹, M.D. Voskuil¹, M. Rivas², R. Xavier², M. Daly², G. Dijkstra¹, E.A. Festen¹, R.K. Weersma¹

Created: Thursday, 21 February 2019, 9:14 AM

OP011:Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study

Year: 2017

Source: ECCO'17 Barcelona

Authors: Peyrin-Biroulet L.

Last Modified: Wednesday, 15 March 2017, 2:47 PM by ECCO Administrator

Etrolizumab

Files: 1

OP012: IL-23 is centrally involved in mediating molecular resistance to anti-TNF therapy in Crohn’s disease patients

Year: 2018

Source: ECCO '18 Vienna

Authors:

H. Schmitt¹*, U. Billmeier¹, W. Dieterich¹, T. Rath¹, S. Sonnewald², S. Reid², S. Hirschmann¹, K. Hildner¹, M.J. Waldner¹, J. Mudter³, A. Hartmann⁴, R. Grützmann⁵, C. Neufert¹, T. Münster⁶, M.F. Neurath¹, R. Atreya¹

Created: Thursday, 21 February 2019, 9:14 AM

OP012: Perioperative use of vedolizumab is not associated with short-term postoperative infectious complications in patients with Ulcerative Colitis undergoing (procto)colectomy with ileal pouch- anal anastomosis

Year: 2017

Source: ECCO'17 Barcelona

Authors: Ferrante M.

Last Modified: Wednesday, 15 March 2017, 2:49 PM by ECCO Administrator

Ulcerative colitis, Ileo anal pouch procedure, Post operative complications, Post operative medical management, Vedolizumab

Files: 1

OP012: Perioperative use of vedolizumab is not associated with short-term postoperative infectious complications in patients with ulcerative colitis undergoing (procto)colectomy with ileal pouch-anal anastomosis

Year: 2017

Source: ECCO '17 Barcelona

Authors:

Ferrante M.^*1, Schils N.¹, De Buck van Overstraeten A.², Vermeire S.¹, Van Assche G.¹, Wolthuis A.², D'Hoore A.²

Created: Wednesday, 20 February 2019, 10:36 AM

OP012: Risk factors for colorectal neoplasia in ulcerative colitis: results from the largest and longest-running colonoscopic surveillance programme

Year: 2016

Source: ECCO '16 Amsterdam

Authors:

C. H. R. Choi*^{1, 2}, I. Al Bakir^{1, 2}, N. S. J. Ding¹, M. Moorghen¹, S. Thomas-Gibson¹, J. Warusavitarne¹, B. Saunders¹, M. Rutter³, T. Graham², A. Hart¹

Created: Friday, 22 February 2019, 9:49 AM

OP013: Disease management and outcomes of patients with Crohn's disease at high risk of recurrence. Results from PRACTICROHN study

Year: 2017

Source: ECCO '17 Barcelona

Authors:

Iborra M.^*1, Martín Arranz M.D.², Domènech E.³, García V.⁴, Gutiérrez A.⁵, Barreiro-de Acosta M.⁶, Cea-Calvo L.⁷, Romero C.⁷, Juliá B.⁷

Created: Wednesday, 20 February 2019, 10:36 AM

OP013: Disease management and outcomes of patients with Crohn’s Disease at high risk of recurrence. Results from PRACTICROHN study

Year: 2017

Source: ECCO'17 Barcelona

Authors: Iborra M.

Last Modified: Wednesday, 15 March 2017, 2:52 PM by ECCO Administrator

Colonscopy, Ileo caecal resection, Post operative complications, Post operative medical management, Thiopurines ( AZA / MP )

Files: 1

OP013: Evolution of corticosteroid use in Crohn’s disease patients between 1991 and 2014: results from the Dutch population-based Inflammatory Bowel Disease South Limburg cohort

Year: 2016

Source: ECCO '16 Amsterdam

Authors:

S. Jeuring*^{1, 2}, V. Biemans¹, L. Liu¹, T. Van den Heuvel^{1, 2}, M. Zeegers^{3, 4},  W. Hameeteman¹, M. Romberg-Camps⁵, L. Oostenbrug⁶, A. Masclee^{1, 2}, D. Jonkers^{1, 2}, M. Pierik^{1, 2}

Created: Friday, 22 February 2019, 9:49 AM

OP013: HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn’s disease

Year: 2018

Source: ECCO '18 Vienna

Authors:

A. Sazonovs¹*, N.A. Kennedy², C. Bewshea², L. Moutsianas¹, G.J. Walker², K. De Lange¹, J. Goodhand², C. Anderson¹, J. Barrett¹, PANTS Investigator Consortium, T. Ahmad²

Created: Thursday, 21 February 2019, 9:14 AM

OP013: HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn's Disease

Year: 2018

Source: ECCO'18 Vienna

Authors: Sazonovs Aleksejs

Created: Friday, 23 March 2018, 12:23 PM

Last Modified: Thursday, 5 July 2018, 10:50 AM by Lindley Fritze

OP014: A multicentre, double-blind, placebo-controlled phase 3 study of ustekinumab, a human interleukins-12/23p40 mab, in moderate-severe Crohn’s disease refractory to anti-tumour necrosis factor α: UNITI-1

Year: 2016

Source: ECCO '16 Amsterdam

Authors:

P. Rutgeerts*¹, C. Gasink², M. Blank³, Y. Lang², J. Johanns², L.-L. Gao², B. Sands⁴, S. Hanauer⁵, B. Feagan⁶, S. Targan⁷, S. Ghosh⁸, W. de Villiers⁹, J.-F. Colombel¹⁰, S. Lee¹¹, P. Desreumaux¹², E. V. Loftus, Jr¹³, S. Vermeire¹⁴, W. J. Sandborn¹⁵

Created: Friday, 22 February 2019, 9:49 AM

OP014: Analysis of 1792 gut metagenomes reveals microbial treatment targets for Inflammatory Bowel Disease and irritable bowel syndrome

Year: 2018

Source: ECCO'18 Vienna

Authors: Vich Vila Arnau

Created: Friday, 23 March 2018, 12:23 PM

Last Modified: Thursday, 5 July 2018, 10:51 AM by Lindley Fritze

Files: 1

OP014: Analysis of 1792 gut metagenomes reveals microbial treatment targets for inflammatory bowel disease and irritable bowel syndrome

Year: 2018

Source: ECCO '18 Vienna

Authors:

A. Vich Vila¹*, F. Imhann¹, V. Collij¹, S.A. Jankipersadsing¹, T. Gurry², Z. Mujagic³, A. Kurilshikov¹, M.J. Bonder¹, J. Xiaofang², E. Tigchelaar¹, J. Dekens¹, V. Peters¹, M.D. Voskuil¹, M.C. Visschedijk¹, F. Eleonora A.M.¹, G. Dijkstra¹, A.A. Masclee³, M.H. Hofker¹, R. Xavier⁴, E.J. Alm², J. Fu¹, C. Wijmenga¹, D.M. Jonkers³, A. Zhernakova¹, R.K. Weersma¹

Created: Thursday, 21 February 2019, 9:14 AM

OP014: Histological remission is predictive of improved clinical outcomes in patients with Ulcerative Colitis: Results from the TOUCHSTONE OLE

Year: 2017

Source: ECCO'17 Barcelona

Authors: Feagan B.

Last Modified: Wednesday, 15 March 2017, 2:49 PM by ECCO Administrator

Ozanimod, Histological remission

Files: 1

OP014: Histological remission is predictive of improved clinical outcomes in patients with ulcerative colitis: results from the TOUCHSTONE open-label extension

Year: 2017

Source: ECCO '17 Barcelona

Authors:

Sandborn W.¹, Feagan B.^*2, D'Haens G.³, Levesque B.², Pai R.⁴, Hanauer S.⁵, Wolf D.⁶, Vermeire S.⁷, Ghosh S.⁸, Li C.⁹, Penenberg D.⁹, Aranda R.⁹, Olson A.⁹

Created: Wednesday, 20 February 2019, 10:36 AM